ThermoGenesis (THMO) - מזומנים למניה

ThermoGenesis is a reputable developer of stem cell processing automation systems that prioritizes material biosafety. The cash per share forecast demonstrates the issuer's liquidity, with the indicator currently standing at 0.15. ThermoGenesis generates revenue through the supply of cell therapy equipment and consumables. Stable plant utilization and facility modernization ensure high production continuity for blood separators.
פילוחים אנליטיים של חברת ThermoGenesis

Liquidity serves as the foundation for the survival of ThermoGenesis (THMO) within the high-tech biobanking sector. An analysis of cash per share allows for an assessment of the company's internal reserves for developing cell therapy automation systems. This metric is calculated by dividing total cash holdings by the number of outstanding shares. Growth in this metric confirms financial stability, whereas stagnation may signal a deficit of investment ideas. This indicator serves as a fundamental filter for determining the asset's fair value.